FSD Pharma Study Could Provide Some Much-Needed Relief

In this market news, FSD Pharma Inc. (CSE:HUGE), one of the Canadian marijuana stocks, said it has launched a pilot clinical study for the treatment of irritable bowel syndrome (IBS)


SmallCapPower | November 7, 2018: FSD Pharma Inc. (CSE:HUGE), one of the Canadian cannabis stocks, announced recently the launch of a pilot clinical study with its strategic RD partner, SciCann Therapeutics. The study is intended to test the safety and efficacy of SciCann’s proprietary “Steady Stomach” cannabidiol (CBD) combination product for the treatment of irritable bowel syndrome (IBS) patients. This study follows the previously-reported efficacy results from a preclinical study in rodent models, which demonstrated a three-fold increased efficacy in lowering abdominal inflammation levels with the advanced combination product as compared to CBD alone.

For Our Complete Coverage Of Canadian Marijuana Stocks Click Here   

Learn more about

... read more at: https://smallcappower.com/news/market-news/fsd-pharma-huge-canadian-cannabis-stocks/

by

Leave a Reply